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Engaging with Health Markets in Low and Middle-Income Countries 
 
Gerald Bloom, Annie Wilkinson, Hilary Standing and Henry Lucas 
 
 
Summary 
 
Many low and middle-income countries have pluralistic health systems with a variety of 
providers of health-related goods and services in terms of their level of training, their 
ownership (public or private) and their relationship with the regulatory system. The 
development of institutional arrangements to influence their performance has lagged behind 
the spread of these markets. This paper presents a framework for analysing a pluralistic 
health system. The relationships between private providers of health services and 
government, or other organisations that represent the public interest, strongly influence their 
performance in meeting the needs of the poor. Their impact on the pattern of service delivery 
depends on how the relationships are managed and the degree to which they respond to the 
interests of the population. Many governments of low and middle-income countries are under 
pressure to increase access to safe, effective and affordable health services. In a context of 
economic growth, it should be possible to improve access by the poor to health services 
substantially. Innovations in information technologies and in low cost diagnostics are creating 
important new opportunities for achieving this. It will be important to mobilise both public and 
private providers of health-related goods and services. This will involve big changes in the 
roles and responsibilities of all health sector actors. Governments, businesses and civil 
society organizations will need to learn how to make pluralist health systems work better 
through experimentation and systematic learning about what works and why.  
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Introduction 
 
The Centre for Business and Development has several reasons for making health one of its 
priority sectors. These include the size of the health sector, the importance of access to safe, 
effective and affordable health services to individuals and to the businesses, which employ 
them, and the degree to which health systems are changing in a context of rapid, market-led 
economic growth, technological innovation and globalization.  
 
 According to data published by the WHO (2014), expenditure on health services accounted 
for 10 percent of global GDP in 2011, varying from 3.6 percent in the Southeast Asia Region 
(SEARO) to 14.8 percent in the Region of the Americas (PAHO). A significant proportion of 
this expenditure (40.2 percent) was from non-government sources, varying from 24.6 percent 
in EURO to 63.0 percent in SEARO. These percentages underestimate the economic 
importance of health and health services since they do not include the value of unpaid time 
that family members spend caring for the sick and they do not include the loss of productivity 
when someone falls ill. This highlights the potential significance of measures to improve 
health sector performance. 
 
Health and health services are important to all social groups, including the poor. Almost all 
governments in the immediate post-colonial and post-revolutionary periods promised to 
provide universal access to health services. These commitments were expressed in national 
policies and global commitments to the achievement of “Health for All”, although in many 
cases, these ambitious goals were not reached. Studies of the viewpoints of the poor have 
consistently found that they give high priority to services that help them cope with major 
illnesses, which can disrupt livelihood strategies and drive them deeper into poverty. These 
factors have made health a political issue in many countries and a number of governments 
have made renewed commitments to achieve universal health coverage (UHC). Many 
international organisations, donor agencies and foundations have made support for UHC a 
priority. Substantial progress towards this goal will require, amongst other things, big 
improvements in the performance of markets for the medical care and drugs that poor people 
need. 
 
Sickness and poor health affects businesses through reduced productivity of their employees 
and the loss of skilled personnel. Where businesses provide their employees with health care 
or access to health insurance, they bear a share of the costs of ineffective and unnecessarily 
costly services. These employers have a direct interest in measures to improve health 
system performance. Businesses can also have a negative impact on the health of their 
employees or of the wider community if they do not pay attention to occupational health or 
environmental pollution. 
 
Market relations have spread rapidly within the health sectors of many countries (Bloom et al 
2013). In 2011 out-of-pocket payments accounted for 25.5 and 50 percent of total health 
expenditure from the Africa and Southeast Asia regions of WHO, respectively (WHO 2014). 
Although some of these funds were paid as fees to government facilities they were also used 
to purchase health-related goods and services in the market. A number of studies suggest 
that more than half of health care visits are to informal providers in a number of countries 
(Sudhinaraset et al 2013) The spread of health markets has been associated with a variety of 
factors that include economic crisis and prolonged financial constraints in the public sector, 
major increases in the role of markets in development strategies and growing demand for 
health services linked to rising incomes, ageing populations and rapid growth in access to 
communications media (Bloom and Standing 2008). The creation of appropriate institutional 
arrangements to encourage good performance by market actors has lagged behind this 
development. The spread of health-related markets has created both opportunities and 
challenges. It has enabled many people to get better access to drugs and some form of 
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medical advice at a relatively small cost. But, it has been associated with a number of 
problems with the safety, effectiveness and cost of basic health care and with the lack of an 
effective referral system for the poor (Peters and Bloom 2012).  
 
The demand for health goods and services has risen substantially in countries that are 
experiencing rapid and sustained economic growth. This is creating important market 
opportunities to which firms are responding. It is also opening up big opportunities for testing 
new ways of organising the health sector, without the major constraints to innovation that the 
complex institutional arrangements in the advanced market economies represent (Ehrbeck et 
al 2010). The new technologies and new organisations that emerge are likely to have a 
significant impact on national and global markets for health-related goods and services. 
 
Technologies, such as use of mobile phones and low cost point of care diagnostic tests, are 
evolving rapidly, as are private companies that are trying to build new markets, based on 
these technologies. Some analysts argue that disruptive innovations, such as these, could 
lead to a major transformation in health system organisation. This is contributing to a growing 
interest in strategies for encouraging the development of innovations, which could benefit the 
poor, and in strategies for managing major health system changes to ensure that the needs 
of the poor are taken into account (Christensen et al 2009). 
 
There is a high degree of inter-connection between local, national and global market actors 
and between health and related sectors. Large international companies from the advanced 
market economies and the rising powers are increasingly operating in markets about which 
they know very little. Meanwhile, poorly functioning markets in one locality can have major 
global consequences, such as the emergence of treatment resistant organisms and the 
undetected spread of a pandemic disease. It is becoming increasingly difficult to separate 
national and global levels of regulation and standard-setting (van Zwanenberg et al 2012) 
 
Until recently, discussions about health markets have largely been about the appropriate 
roles of public and private actors in the delivery of health services. These discussions were 
strongly influenced by competing ideological preferences. One result is that most research 
on health systems in low and middle-income countries has focused on the public sector. 
Studies of the private sector have tended to be concerned with quantifying its size and 
comparing the quality of its services with those of the public sector. But health systems in 
these countries have increasingly been characterised by pluralism and marketisation, where 
the boundaries between public and private are porous and many actors with different 
relationships to states and markets provide goods and services to different population groups 
(Mackintosh and Koivusalo 2005; Bloom and Standing 2008). A recent systematic review of 
evidence on strategies for improving the performance of health markets in low- and middle-
income countries (Leonard et al 2013) noted that there has been much less analysis of the 
pluralistic health systems that have spread so widely and of effective strategies for managing 
them. 
 
This paper draws on the findings of several years of collaboration between the authors and 
partners in the DFID-funded Future Health Systems Consortium of research institutes in 
Africa and Asia, under the leadership of the Johns Hopkins School of Public Health. During 
2006-11 the consortium’s work on health markets focused on the role of informal providers in 
Nigeria, India and Bangladesh (Bloom et al 2013). In December 2012 it organised a meeting 
in Bellagio with government policy-makers, health system entrepreneurs, researchers and 
funders of intervention research to review the state of knowledge and identify priorities for 
engaging with health markets. Many of the findings are available in a special issue of 
Globalization and Health, which focuses on the challenge of regulation and on strategies for 
facilitating learning about the functioning of rapidly changing health markets (Bennett et al 
2014; Bloom et al 2014 and Stallworthy et al 2014). The second phase of work, until 2016, 
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focuses on the emergence and diffusion of potentially disruptive innovations and on 
managing change in complex and dynamic contexts.  
 
The remainder of the paper is structured as follows: section 2 introduces health markets and 
the pluralistic health systems of low and middle-income countries; section 3 focuses on 
potential strategies for engaging with and bringing order to these markets; section 4 explores 
selected technological developments that have the potential to disrupt health markets and 
section 5 concludes with a brief discussion of activities for generating knowledge for more 
effective engagement with health-related markets. 
 
1 Analysing a pluralistic health system 
 
Analysts almost unanimously agree that unregulated markets perform badly in meeting a 
population’s health needs. Table 1 lists widely acknowledged failures of health markets. This 
paper focuses on curative medicine, which is largely a transaction between providers and 
recipients of services (Harding and Preker 2002). It pays little attention to health promotion 
and prevention, which have a substantial public goods element. It also does not discuss 
alternative ways to provide financial protection and reduce economic barriers to care, 
although these are essential elements of a health system that meets social needs. The 
market failure especially relevant to personal medical care concerns asymmetry of 
information between providers and users of health-related goods and services (Bloom et al 
2008; Leonard et al 2013). This refers to the differences between them in the levels of expert 
knowledge they possess.  Potential users need to be able to identify providers who have the 
necessary expertise and can be trusted to act in the interest of their patients (Gilson 2003). 
Providers of services need to be confident they will be rewarded for providing high quality 
and trustworthy advice and services. In the absence of appropriate institutions to manage 
information asymmetry, there is a risk that experts will use their power to charge patients for 
unnecessary services and/or clients will be unwilling to pay fees to health workers, whose 
knowledge and expertise they cannot assess. Both outcomes are commonly found. 
 
 
Table 1.1 ‘Market failures’ in the health sector 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The advanced market economies have addressed these problems with powerful professions, 
government purchase and provision of services and highly regulated pharmaceutical and 
medical equipment industries, all underpinned by social and ethical norms of behaviour. 
These arrangements have evolved over decades and reflect local social and political history 
(Bloom and Standing 2008). A number of analysts have argued that health systems are 
highly path dependent, because of political pressure to avoid changes that might threaten the 
ability of a health system to meet the established expectations of the population. Low and 
 Health-related services include public goods such as public sewerage and water supply 
systems, which are often undersupplied if left to the market. 
 Health decisions based only on individual needs are likely to result in sub-optimal funding 
patterns, as some services – such as immunisations – have wider societal benefits. 
 Markets tend to under-insure against major health expenditure because they cannot 
control costs effectively and there is little incentive for a healthy person to join an 
insurance scheme. 
 Markets may not adequately reflect the greater willingness of the population to finance 
basic health care as compared to non-health goods and services. 
 Markets can worsen distributive outcomes and hence health inequities. 
 Markets for goods and services that embody expert knowledge produce information 
asymmetry between providers and clients that can make clients vulnerable to abuse of 
provider power and/or reduce the level of trust that clients have in providers. 
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middle-income countries need to build on their own institutional inheritance to find innovative 
solutions to the challenge of asymmetric information (Leonard et al 2013). 
 
The view that health is a ‘special case’, guided by the principles of ‘do no harm’ and ‘put the 
needs of a patient first’, has led many health policy analysts to view engagement with 
markets as inappropriate. Yet, market relationships have become pervasive in the health 
systems of many low- and middle-income countries. In the pluralistic systems that have 
emerged, there are a wide variety of providers of services and drugs in terms of their training, 
their skills and their relationship with the formal regulatory system. The boundaries between 
public and private sectors have become porous as government health workers accept cash 
payments (official or informal), practise privately and establish informal links with the private 
sector. Policy interventions that ignore this reality may fail to exploit its potential and can 
have unintended outcomes (Bloom et al 2008). However, the effective management of 
pluralistic health systems requires new understandings of the influences on their 
performance and of the governance and stewardship roles of the state (Ahmed et al 2013; 
Lagomarsino et al 2009).  
 
Figure 1 provides a framework for analysing a pluralistic health system. At the centre are the 
users and providers of health advice, services and/or drugs. They are influenced by a variety 
of actors, which perform a number of functions. This influence is mediated through different 
types of formal and informal relationship. An intervention aimed at improving the 
performance of particular health service providers needs to take these relationships, and the 
likely responses of different actors, into account. 
 
The boundaries of a health system and the actors included in an analysis depend on the 
particular goods and services the analyst is studying. For example, providers of services for 
common health problems, for reproductive health services and for mental illness may be 
quite different. The boundaries also depend on the problems to be solved, or social 
objectives to be achieved. This paper takes a normative position which prioritises the 
provision of access to safe, effective and affordable health care for the common health 
problems of the poor. This is consistent with the current global objective of universal health 
coverage.   
 
Although individual providers are typically located near to their clients, they are often linked 
to larger organisations. It is therefore important to include relevant aspects of the local, 
national and global levels in a health system analysis. The following paragraphs describe the 
types of actors commonly involved in the provision of drugs and outpatient services in 
countries with pluralistic health systems. 
 
By users we mean the general public who make up the ‘demand side’. There are many ways 
to categorise users and the factors shaping their health and health seeking. At different times 
users may interact with the health system as patients, as individuals ‘at risk’ of a disease, or 
as healthy individuals. As countries develop economically and living standards rise, the 
threat of infectious disease tends to lessen, people live longer and non-communicable 
diseases account for more of the disease burden. Many countries now face a double burden 
of disease, where infectious diseases remain a problem, but chronic and non-communicable 
diseases are increasingly prevalent. Age, gender, cohort and genetic factors fundamentally 
shape demand-side need and behaviour. Within societies there is usually a social gradient to 
morbidity, with the rich tending to be healthier. As well as the determinants of disease there 
are important economic determinants of health-seeking behaviour. Cost of healthcare, and 
the cost of transport to healthcare, can be a significant demand-side barrier. As a result, in 
many healthcare markets the poor tend to rely on informal private healthcare providers, who 
may not charge for consultations or who will accept delayed payment. Typically, health-
seeking behaviour and treatment preferences are also influenced by a patient’s knowledge 
and experience of the local health system: past illness episodes, their education, their social 
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networks, and the perceived quality and attitude of healthcare providers. In short, a complex 
and interacting range of social, political, economic and biological determinants influence user 
demand.        
 
Figure 1.1 Conceptualizing a pluralistic health system 
 
 
Source: Adapted from Elliot et al. (2008) 
 
 
The supply side includes individuals and organisations that define themselves primarily as 
service providers or drug sellers, although providers frequently sell drugs and pharmacies 
advise clients on which drugs to use. It is difficult to define what qualifies as a “business” in a 
pluralistic health system, where the regulatory arrangements are neither highly developed 
nor rigorously enforced. The formal status of an organisation as publicly owned, a large or 
small enterprise, a not-for-profit organisation, a faith-based organisation or a social 
enterprise is often not a good predictor of behaviour. For example, a recent study in India 
found no difference between public, private and informal health workers in the quality of care 
of some common conditions (Das et al 2013). The performance of both public and private 
providers is influenced by factors such as the internal “mission” of the organisation, the terms 
and conditions of employment and career progress, financial and other incentives, formal 
and informal rules, prevalent ethical norms of behaviour, accountability mechanisms and 
widely accepted social norms (Macintosh and Tibandebage 2002; Leonard et al 2013).  
 
An explicit or implicit acceptance of a variety of market-like activities has blurred the 
boundaries between public and private sectors in many countries. In China, for example, 
government-owned facilities rely heavily on payments by patients and compete fiercely for 
business. The Chinese Government uses a combination of regulation, direct management 
intervention and strategies for engaging with markets, such as performance-related 
contracts, to influence their behaviour. Elsewhere, the inter-connections between public and 
private providers are largely informal, in the sense that regulation is either lacking or poorly 
implemented. Governments of these countries face a choice between implementing major 
reforms to the public sector to (re-) establish a fully salaried public service, a very expensive 
and difficult to enforce option in many countries, or taking measures that recognise the 
influence of market relationships in the public sector. These measures might include signing 
contracts with individuals or facilities and the production and dissemination of monitoring 
indicators. 
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A large proportion of economic activity takes place outside the legal framework in many low 
and middle-income countries. This certainly applies to the health sector, with poor people 
relying largely on unlicensed suppliers of health services and drugs for treatment of common 
diseases in a number of cases (Sudhinaraset et al 2013). The degree to which these 
providers meet health needs is unclear. On the one hand, a recent study in Bangladesh 
suggests that the supply of antibiotics by informal village doctors has contributed to falls in 
maternal and childhood mortality from infections (National Institute of Population Research 
and Training 2012). On the other hand, other studies have revealed problems with sub-
standard drugs, inappropriate prescriptions, high levels of unnecessary spending and weak 
links with the rest of the health sector, leading to delayed referral and lack of notification of 
potential epidemics (Bhuiya 2009; Ali et al 2012). One policy option would be to eliminate 
these unorganised markets, but this would only be politically feasible if higher quality sources 
of health care were made at least as accessible and acceptable to potential clients. The 
alternative is to find ways to improve their performance (Shah et al 2011; Peters and Bloom 
2012).  
 
The existence of unorganised markets makes it necessary to differentiate between a 
legitimate business and a criminal enterprise. In India and Bangladesh, for example, many 
licensed doctors refer to informal providers as “quacks” and “thugs”, citing examples of highly 
exploitative behaviour. But, the clients of many of these providers trust them and hold them 
in high esteem for their accessibility, flexibility over payments and better interpersonal 
attitudes (Gautham et al 2013; Bhuiya et al 2009; Oladepo and Lucas 2013) This may 
explain their persistence for decades, despite illegally selling prescription drugs. This 
contrasts with attitudes towards producers and suppliers of sub-standard drugs or addictive 
narcotics, who are widely perceived to be profiting from harmful activities. This difference in 
public understanding and tolerance may partially explain why the drug regulatory agency in 
Nigeria was able to pursue a concerted campaign to eliminate counterfeit drugs in a context 
of generally weak governance (Garuba et al 2009). Measures to influence health markets 
need to be based on both an objective assessment of the technical quality of provider 
performance and a contextual understanding of trust and what is regarded as legitimate and 
illegitimate behaviour.  
 
Front-line providers of health-related goods and services are influenced by other 
organisations. These include providers of more sophisticated health services with whom they 
compete but to whom they refer patients, often in return for payment. They are also 
influenced by the producers and distributors of drugs and diagnostic services. A recent study 
in Bangladesh documented how representatives of pharmaceutical companies supply 
informal village doctors with information on their products and offer financial incentives to 
stock them (Rahman et al 2010). Another study found that one of the large Bangladeshi 
pharmaceutical companies maintains a database of more than 180,000 informal drug sellers 
and organises regular meetings with them (Bloom et al 2014). A study in Tanzania also 
found that rural pharmacies were more likely to stock products produced and distributed in 
that country than imported products (Mujinja et al 2014). These studies demonstrate the 
influence of the organisation of the drug value chain on both the availability of drugs to poor 
clients and the type of advice the drug sellers provide.  
 
The flow of health information and advice has been undergoing rapid change in recent years. 
A very high proportion of people have access to radio and, increasingly, to television. There 
has been a growth in advertising agencies and advocacy organisations that produce content 
aimed at informing and influencing health-related decisions. More recently the spread of 
mobile phones has led to a growing influence on the content and sources of health 
information of mobile phone operators, internet providers and other types of knowledge 
intermediary. These developments are increasingly influencing providers and users of health 
services and mark a departure from the more traditional form of health advice mediated by 
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medical professionals. They raise important questions about quality and about whose 
interests are being promoted or represented. 
 
As the integration of the global economy has proceeded, it has become important to take into 
account the role of transnational pharmaceutical and service delivery companies (both for-
profit and not-for-profit). These organisations are influenced by their home country’s legal 
frameworks and their relationships with their own government. Companies and NGOs from 
rapidly growing large low and middle-income countries are becoming global actors.  
At the local level, a number of civil society organisations also influence the performance of 
pluralistic health systems. These include representative bodies, such as professional bodies, 
trade associations and, in some countries, associations of informal providers and drug sellers 
(Oladepo and Lucas 2013; Gautham et al 2013). These bodies represent the interests of 
their members, but they may also play a role in assuring the quality of their members’ 
performance. There are often strong conflicts of interest between the associations that 
represent different types of provider. In a number of countries, for example, the 
representatives of medical doctors have successfully opposed measures that could 
strengthen their competitors, including paraprofessionals and informal providers (Dussault 
2008).  
 
Organisations that represent people as citizens, patients and/or carers are becoming 
increasingly important. The most prominent have been the diverse advocacy groups that 
successfully lobbied for governments and the global community to provide access to 
antiretroviral therapy for people with HIV/AIDS. The rapid growth in access to 
communications media, especially mobile phones, has accelerated the development of a 
multiplicity of such organisations at local, national and international levels, often promoting 
the interests of those with a very specific health condition and composed of a diverse range 
of stakeholders that may include not only patients, carers and clinicians but pharmaceutical 
and health care companies. There are also examples of consumer groups and community 
organisations, for example Health Watch in Bangladesh, that advocate for improvements in 
the performance of health markets. 
 
Finally, a wide variety of government agencies influence pluralistic health systems. These 
include agencies that license health workers and accredit facilities, national regulators of 
trade and industry and sub-national regulators of small and medium enterprises. There is 
often a gap between the formal regulations and their enforcement. Countries with relatively 
weak governance structures often have detailed regulatory frameworks that strictly define the 
rules within which those operating in the health sector must function. However, they typically 
do not have the capacity, or in some cases the will, to ensure that these frameworks are 
effective. In many countries the formal health sector is so restricted in accessibility that strict 
enforcement of existing regulations would severely limit access to any form of health services 
by the poor. 
 
The previous paragraphs note the stakeholders that influence the performance of pluralistic 
health systems. They vary in their power, their short and long-term interests and their 
understandings of the context within which they operate. A number of analysts have 
highlighted the need for government to play a stewardship role in ensuring that the interests 
of all stakeholders, including the poor and politically weak, are taken into account 
(Lagomarsino et al 2010). The capacity of government to play this role depends on its 
technical expertise and the degree to which it has legitimacy as a representative of the 
common good. It also depends on the capacity of other stakeholders to play an effective role 
in building relationships and creating effective institutional arrangements. The following 
section explores these issues. 
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2 Engaging with health markets 
 
This section is concerned with the relationships between providers of health-related goods 
and services and a variety of entities that influence their performance. These include other 
private providers of drugs and health services, membership organisations, not-for-profit 
organizations, representative bodies and government agencies (figure 1). It focuses on the 
outpatient services used by the majority of the population. It argues that the institutional 
arrangements within which health markets are embedded are co-constructed by 
stakeholders. These arrangements include formal regulations and informal rules, backed by 
widely accepted norms of what constitutes socially acceptable behaviour (Leonard et al 
2013). It is important to recognise the dynamic nature of these arrangements and the political 
nature of co-construction. Health institutions are highly path dependent, reflecting the 
historical legacy and beliefs about basic rights, entitlements and responsibilities. They are 
also dynamic; new structures can emerge as a result of constant testing of new ways to 
address problems. The challenge for governments and political leaders is to oversee the 
creation of institutions that support markets in meeting social objectives, such as the 
provision of access to safe, effective and affordable health services, whilst reducing the risk 
of harmful activities, such as the sale of sub-standard drugs or the provision of damaging 
treatments. The following paragraphs use the lenses of regulation and partnership to explore 
institution-building in pluralistic health systems.  
 
Regulation 
A number of studies have shown the lack of appropriate and effective health regulatory 
systems in many low and middle-income countries (Alfifi et al 2005; Ensor and Weinzierl 
2006; Sheik et al 2012; Bloom et al 2014). A narrow view of regulation views it as a 
government function involving administrative and bureaucratic controls to correct market 
failures (OECD 1997).This kind of regulation plays an important role in protecting the public 
against incompetent medical practices and dangerous medicines in many countries. 
However, it has limitations because of the paucity of information about health markets 
available to the state, the lack of capacity to enforce regulations and the potential for capture 
of the state by special interests or by its own rent-seeking officials. Another view is that 
regulation is the outcome of a series of relationships between states, enterprises and civil 
society organisations (Black 2002; Smith 2004; Bourgon 2011). This “decentred” 
understanding of regulation recognises that states, on their own, cannot ensure the effective 
functioning of complex markets that involve relationships between a number of stakeholders. 
It also recognises that regulatory systems are co-constructed by the state and other 
stakeholders. The capacity of the state to participate effectively in this co-construction 
strongly influences outcomes. 
 
Bloom et al (2014) advocate a multi-pronged approach to health market regulation, which 
takes into account the different types of relationship with a regulatory aspect. These include 
relationships between the state and enterprises, between enterprises, between enterprises 
and other organisations and within an enterprise. They argue that this approach needs to be 
tailored to local contexts and adjusted as a market system develops and evolves. New ideas 
may emerge out of local innovations or they may be introduced as experimental 
interventions. There is likely to be an extended period of testing and revision as new ways of 
doing business go to scale. They identify four complementary regulatory strategies. 
• Administrative and bureaucratic controls such as the criminalization of malpractice, 
licensing and accreditation of providers and facilities and registration of products 
• Market-supply oriented approaches such as self-regulation, contracting, creation of 
franchises, incentives and subsidies, disclosure and management improvement 
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• Consumer or citizen-oriented approaches such as consumer education, a right to 
information by citizens, consumer rights, patient redress, citizen empowerment and 
liability norms 
• Collaboration oriented approaches including co-production of services and regulation 
across key stakeholders and partnerships for transparency and accountability. 
 
Regulation takes place at local, national, regional and international levels. Global and 
regional initiatives play an important role in generating agreement on broad objectives, 
involving global actors such as national governments, transnational organisations (for profit 
and not-for-profit), and global bodies that establish regional or international standards. 
However, it is important to recognise the significant influence of the advanced market 
economies in setting standards which rarely take into account the context of informal markets 
(van Zwanenberg et al 2010).  
 
Reforming a regulatory system cannot be driven from outside national boundaries. The 
ultimate aim is to establish rules that the majority of stakeholders consider to be legitimate 
and that they internalise as behavioural norms. The outcome of this kind of institution-
building will be strongly influenced by the degree to which different social groups can 
mobilise to ensure that political leaders take their interests and perspectives into account. 
There is little systematic evidence on what works in building effective institutional solutions to 
the problem of asymmetric information in low and middle-income countries. These countries 
will have to pursue a learning-by-doing strategy, in which they test alternative interventions 
and build on what succeeds (Peters et al 2009). 
 
Partnership 
A second lens through which to examine health sector institutions is partnership. Interest in 
this perspective has been stimulated by action at global level to build public-private 
partnerships (PPPs) involving large international organisations, philanthropies, NGOs and 
corporations with a variety of aims as outlined below. The governments of many low and 
middle-income countries have managed a wide variety of partnerships with non-state 
organisations for years. These have included co-funding agreements with faith-based health 
facilities, contracting for a variety of services and regulatory partnerships. This paper uses a 
modified version of the working definition for PPPs proposed by Reich (2002): involving at 
least one private-for-profit organization and one not-for-profit or public organization with the 
partners having some shared objectives for the creation of social value and an agreement by 
the core partners to share efforts and benefits. We argue that governments and other 
stakeholders in countries with pluralistic health systems need to build on this experience to 
create and manage new partnerships to address major health system problems more quickly 
and at scale.   
 
A wide variety of PPPs have emerged to address the health needs of low and middle-income 
countries (Widdus 2001; Brinkerhoff and Brinkerfoff 2011; Nishtar 2006). These include: 
• Policy, public advocacy  and education-building coalitions around developing specific 
health programmes or addressing specific regulatory challenges 
• Public funding of private company research and development of drugs, vaccines and 
medical technology with the potential to improve access to services by the poor, at 
scale 
• Investment in the construction of facilities, such as hospitals 
• Partnerships for service delivery and strengthening of health services through public 
funding of services provided by non-state providers of health and through supply of 
subsidized drugs and other products by private companies 
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• Regulation and quality assurance through partnerships to regulate drug quality and 
safety, social franchising of service providers and private participation in governance 
bodies 
• Global coordination of major initiatives such as by the Global Fund for HIV, malaria 
and TB and GAVI. 
 
Partnerships intended to contribute to the provision of access to safe, effective and 
affordable health services may involve a variety of stakeholders. These relationships can be 
largely between private, for-profit and not-for-profit actors, they can involve associations of 
providers and they can involve citizens’ organisations (figure 1). What is important is the 
degree to which the partnership addresses an agreed public purpose, as well as the specific 
objectives of each partner. The tensions between individual interests and the agreed 
partnership objectives are intrinsic to this kind of partnership.  
 
The creation and maintenance of an effective partnership requires an investment of time and 
money. A review of health PPPs for the World Economic Forum (2005), for example, 
emphasised the effort needed to create governance arrangements, particularly when these 
partnerships go to scale. Brinkerhoff and Brinkerhoff (2011) propose several reasons why 
stakeholders invest in this kind of initiative (i) to enhance efficiency and effectiveness through 
reliance on comparative advantages; (ii) to provide the multi-actor resources needed to 
address particular problems:- (iii) to move towards compromise and potential win-win 
situations and (iv) to open decision-making processes to promote a broader 
operationalization of the public good. 
 
For a partnership to survive it is important that each partner believe that the benefits it 
derives from the effort of creating and maintaining the partnership outweigh the potential 
losses from the constraints to pursuing its narrow interests. They also need to believe that 
the distribution of downside risk is shared fairly. The way a partnership balances the interests 
of its members reflects the governance arrangements put in place and the relative power of 
the different partners (Buse and Harmer 2004). Much of the debate about the desirability of 
PPPs reflects different views about the possible capture of a partnership by powerful 
stakeholders and of the capacity of governments and other stakeholders to provide an 
effective countervailing influence and protect the public interest. Buse and Harmer (2004) 
point out that there is little systematic evidence about the political economy of these 
partnerships and its influence on their outcome.  
 
Building institutions for regulation and partnership 
Discussions of regulation and partnership in the literature present alternative framings of the 
same issue: the role of trust-based relationships in ensuring the quality of health system 
performance and the need to build institutional arrangements to support these relationships. 
Previous efforts to build the institutions for a modern health system in low and middle-income 
countries have focused on the replication of the arrangements in advanced market 
economies. The results have often fallen well below expectations and in a number of 
countries the outcome has been the emergence of the largely unregulated pluralistic systems 
of health care described above. There is limited evidence about the approaches that work 
well in building institutions in low and middle-income countries (Fukiyama 2004; Chang 
2007). This has led to a recognition of the inherent complexity of health systems and of the 
need for a learning-by-doing approach to the management of change (Peters et al 2009; 
Bloom and Wolcott 2013).  
 
In the context of the advanced market economies, Fligstein (2001) argues that successful 
private companies strive to achieve both immediate market advantage and the creation of an 
institutional framework that provides stability for future growth and development. This stability 
depends on attaining a degree of social legitimacy, which makes it possible to enforce rules 
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effectively. This means that their behaviour reflects the need to both protect and build their 
market share and co-produce a stable institutional framework that is perceived to be in the 
public interest. Governments play a central role in creating and enforcing the regulatory 
framework. Governments and other stakeholders face special challenges in promoting the 
development of appropriate institutional arrangements in countries with pluralistic health 
systems. The emergence of these systems has typically been in countries with either a 
history of weak governance or undertaking radical changes in development strategy, for 
example transition from command economies (Leonard et al 2013). In both cases, strategies 
for change need to take into account the lack of deeply embedded formal institutions and, in 
some cases, generally accepted behavioural norms. This often means that there is a lack of 
a shared vision of the roles and responsibilities of the different stakeholders, leading to a 
predominance of short-term considerations in decisions. One way of addressing this issue is 
to identify specific problems that lend themselves to attempts at consensus building around 
possible solutions in the hope that a successful experience will provide lessons for dealing 
with more difficult issues. 
 
A second challenge is the imbalance of power and the different understandings and visions 
between the government and other national stakeholders and the transnational companies 
and other organisations that are increasingly engaged in their health economy. For example, 
there may be a conflict between the search by pharmaceutical companies for markets for 
their drugs and the needs of poor people for inexpensive ways to prevent or delay the 
complications of diabetes and hypertension. This raises questions about the degree to which 
these companies can be made accountable to local stakeholders and about the possible role 
of global institutions as influences on the behaviour of these companies. The increasing 
global presence of companies from rapidly growing middle-income countries and the 
consequent involvement of their governments in governance arrangements adds another 
level of complexity, especially since these important global actors are still in the process of 
building institutions to bring order to their own pluralistic health systems.  
 
Large companies are increasingly aware of the tension between their immediate need to 
build market share and their longer-term interest in establishing a stable and long-term 
presence in new markets. In the advanced market economies, they have sought to secure 
their long-term interest through a combination of lobbying, communications efforts and 
promotion of the concept of corporate social responsibility. The rapid growth of markets for 
health-related goods and services has made it increasingly important for companies to find 
ways to build a long-term presence in them. However, in low and middle income countries, 
measures to provide immediate and visible benefits seems to have taken centre stage, with 
much less investment in market forming and stabilising activities. For example, 
pharmaceutical companies have focused mostly on tiered pricing and the provision of low-
cost drugs for diseases of poverty. They have not engaged very much in building institutions 
for market stabilisation to address problems such as the large proportion of drugs that are 
counterfeit and the inappropriate use of many drugs. This balance of activities probably 
reflects a lack of contextual knowledge, the unwillingness of governments to engage with 
them and a lack of confidence in long-term growth and stability. It may also reflect a previous 
reliance on the governments of their home country to protect their interest in the so-called 
“developing world”. 
 
Governments have been reluctant to engage with these companies, because of a concern 
that they are so powerful that they would use this engagement to build monopoly positions. 
Many countries have previous experience with the consequences of this kind of behaviour. 
This highlights the need for governments to build a capacity to lead a process of institutional 
development and to play an effective stewardship role (Lagomarsino et al 2009; Ahmed et al 
2013). 
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The co-existence of highly ordered health systems in some countries and pluralistic systems, 
with chaotic health markets in others is an unstable arrangement. This is putting pressure on 
all actors to find ways to bring more order to national and global health systems. Each has a 
partial understanding of the complex reality and has a particular focus on its own interests. It 
is important to facilitate processes for building mutual understanding of the challenges and 
possible development pathways and to enable all stakeholders, including the poor and 
relatively powerless, to influence policy choices. The outcome of the engagement between 
businesses, government and other health sector stakeholders will be strongly influenced by 
political economy factors. The pathway of development will reflect the way that conflicting 
interests are mediated, the extent to which mutual understanding of the problems and a 
shared vision of the role of the partnership in a future health system can be achieved and the 
degree to which emergent institutions can win political legitimacy.  
 
Governments, businesses and a wide variety of other stakeholders face a big challenge in 
managing and reforming pluralistic health systems. This will require a major effort of learning 
how to establish and manage new kinds of relationship between stakeholders and how to 
participate in the creation of appropriate institutional arrangements. The direction of 
development and the degree to which the health system addresses the needs of the poor for 
access to safe, effective and affordable health services will be strongly influenced by the way 
this process is managed. One of the major areas of research by the Centre for Business and 
Development will be to test possible strategies for this kind of effective engagement. It will 
select high priority problems, for which it will address the following questions:  
• Is the problem clearly defined? 
• Who are the key stakeholders with regard to the problem to be addressed and what 
are their interests in engaging in a partnership? 
• How is the problem to be addressed framed by different stakeholders and how can a 
mutual understanding be built?  
• Can stakeholders agree clearly defined roles and responsibilities concerning the 
problem? 
• How is the tension between the agreed goal and specific stakeholder interests 
managed?  
• Can the state play a stewardship role on its own or in partnership with key 
stakeholders and can the initiative win public legitimacy 
• Is there a process for learning from emergent arrangements and disseminating 
lessons learned? 
 
It is impossible to predict the outcome of any particular intervention. This suggests the 
advantages of beginning with rather focused local interventions to generate information on 
what works and why and then apply the lessons to take the intervention to scale. A focused 
intervention can also provide systematic learning about ways to extend partnerships to 
address other health system problems. Annex I illustrates with the example of the global 
effort to reduce the risk of emergence of resistance to antimicrobial drugs. 
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3 Innovation and health system development 
There is a lot of international interest in the potential role of innovation in increasing access 
to safe, effective and affordable health services (Piot 2012). This has led donor agencies and 
foundations to invest in research and development of technological solutions.  
 
One stimulus to this interest is the belief that new technologies are creating big opportunities 
for improving health services (Pauly 2008; Smith 2007). Christensen et al (2009) argue that a 
combination of developments in information technology and low-cost diagnostics and the 
development of evidence-based treatment protocols make it increasingly possible to employ 
a rules-based approach for diagnosing and managing illnesses. This means that less 
expensive personnel can take over these tasks from physicians. Many conditions can be 
swiftly and cheaply dealt with in walk-in clinics and people can increasingly manage their 
own health problems, particularly for chronic, lifelong conditions, such as diabetes and 
hypertension. These “disruptive innovations” have the potential to change health systems 
substantially. However, resistance by stakeholders and a myriad of complex regulations and 
payment mechanisms may preserve existing arrangements for a long time in the United 
States and other advanced market economies (Lee and Lansky 2008). There may be fewer 
constraints to change elsewhere. 
 
Analysts of markets in rapidly growing middle-income countries have documented the 
emergence of low cost goods and services to meet rapidly rising demand by people, whose 
incomes are rising above subsistence level (Prahalad 2005; Clark et al 2009). There are 
already a number of examples of innovative approaches for providing safe, effective and 
affordable health services. These include: (i) protocol-driven management processes within 
hospitals or primary care providers, (ii) the use of branding, franchising, and accreditation to 
influence the performance of large numbers of dispersed providers of health services and 
drugs and (iii) the growing availability of health information and advice through mobile 
phones and the internet (Ehrbeck et al 2010; Bhattacharya et al 2008; Lowe and Montagu 
2009). Most of these innovations are relatively small-scale and it is difficult to predict how 
quickly they will spread. The rapid take-up of mobile telephone banking is an indicator of the 
rapidity with which new ways of doing business can become established (Batchelor 2012).  
 
These developments have stimulated interest in strategies for stimulating potentially 
beneficial innovations and/or for accelerating their diffusion. A number of agencies are 
financing the development of new drugs, vaccines and ICT applications. These investments 
have had mixed results in improving access by the poor to health services (Frost and Reich 
2008). This has led to greater interest in downstream innovations that improve the delivery of 
the benefits of new technologies to poor people (Batavia et al 2011). One response has been 
the creation by donor agencies of challenge funds in a number of low-income countries to 
support this kind of innovation. There is little systematic evidence on the impact of these 
funds on the diffusion of new approaches at scale. 
 
These findings are consistent with the experience of innovation in other sectors. A number of 
authors employ a systemic approach which views innovation as the outcome of the 
relationships between firms, governments, research organisations and other actors, which 
could include NGOs and activists (Mowery and Rosenberg, 1979; Nelson, 1993, Lundvall, 
1998; Carlsson et al., 2002).  The translation of a new scientific idea or technological 
application into improved benefits for large numbers of people requires innovative activities 
by many different actors. A few analysts have applied this perspective to health (Consoli and 
Mina, 2009). Some have focused on the biotechnology industries, arguing for strengthening 
the capacity of developing countries for technological innovation (Thorsteinsdottir et al., 
2004, Engel et al., 2012). Others have focused on the diffusion of innovation in health 
systems (Atun and Sheridan 2007; Greenhalgh et al 2004). A few papers have analysed how 
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health systems co-evolve with institutions, products and services (Consoli and Mina, 2009, 
Thorsteinsdóttir, 2007).  
 
Several analysts have focused on the degree to which technological change is path 
dependent. The health sector can be viewed as a “socio-technical system” which brings 
together products, knowledge, regulation, user practices, markets, cultural meanings, 
infrastructure and production and supply networks (Geels, 2004). The technologies and 
institutions that comprise a socio-technical system include norms, attitudes and 
infrastructural arrangements, which make them resistant to radical change (Geels and Schot, 
2007, Berkhout et al., 2004). One example from the health sector is the use of point of care 
diagnostics for malaria. Their revolutionary potential has been limited by entrenched socio-
cultural diagnostic practices and test results are commonly rejected when they differ from a 
doctor’s or patient’s opinion (Chandler et al., 2008, Chandler et al., 2012). 
 
A number of authors are exploring how relatively stable socio-technical regimes are 
destabilised or transformed (Turnheim and Geels, 2012, Geels et al., 2004, Geels and Schot 
2007; Smith et al., 2005). They reach similar conclusions to the analysts of disruptive 
innovation (Christensen et al 2009). In both cases they identify different transition pathways, 
which depend on the degree to which new actors disrupt existing markets and the ability of 
established actors to adopt new practices. The major lesson that emerges is that a sequence 
of small changes and adaptations can eventually lead to a tipping point after which 
substantial changes happen. Investments in innovations need to have an eye on both the 
immediate impact and the potential contribution to long term transformation. Government 
actions to create a regulatory framework and encourage new ways of doing business can 
also have an important influence on the longer-term development pathway. 
 
One needs to be cautious in applying concepts developed in OECD countries to the different 
context of a pluralistic health system in a low or middle-income country. On the one hand, 
this context may not display the coherence and alignment implied in the concept of a regime. 
Thus, while pluralistic health systems may provide a fertile ground for incremental 
innovations, large scale change may be harder to govern. On the other hand, there may be 
fewer constraints to major transformation. Romijn and Caniëls (2011), for example, suggest 
that advances in biotechnology and platform technologies, such as ICTs, mean that the 
pathways open to developing countries are fundamentally different to those of the past. The 
trajectory of a development pathway and the degree to which it provides benefits to the poor 
is influenced by the actions of a number of stakeholders and by the regulatory framework 
they put in place (Stirling 2009). It is possible to imagine an ICT-enabled health system that 
provides easy access to trustworthy health information and enables people to manage many 
health problems very inexpensively. It is equally possible to imagine a system that induces 
people to purchase unnecessary and potentially harmful drugs, or that is too expensive for 
most people to use. Governments and other stakeholders need to be able to identify and 
respond to problems as they emerge to reduce the risk of undesirable developments.  
 
The work of the Centre for Business and Development will focus on innovations aimed at 
increasing access to safe, effective and affordable outpatient care for common conditions of 
the poor. These include a combination of new information and communications technologies 
and of low cost point-of-care diagnostics. We will address the following questions: 
• Who are the potential innovators at local, national and global levels and how are 
potentially important innovations spreading? 
• What factors constrain the development and diffusion of appropriate technologies and 
what kinds of investment in innovation can help overcome these constraints? What is 
the evidence from the experiences of “grand challenges” and national innovation 
challenge funds 
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• What new types of knowledge brokers and mediators are emerging and what are the 
implications of these for managing knowledge asymmetries? 
• How can governments and other stakeholders increase their capacity to ensure that 
technological innovations meet the needs of the poor? 
• What are the potential unintended and deleterious outcomes of the spread of new 
technologies and what measures can be taken to reduce the risk of them occurring? 
 
 
4 A learning approach towards engaging with 
health markets 
 
Many governments of low and middle-income countries are under political pressure to 
increase access to safe, effective and affordable health services rapidly. At the international 
level this pressure is expressed in the proposal of multi-lateral organisations, such as the 
World Health Organization and the World Bank, to make universal health coverage (UHC) a 
global development goal. In order to move rapidly towards meeting the health needs of the 
poor it will be important to make good use of all health sector resources that provide services 
to them. In countries with pluralistic health systems this will involve major changes to the 
roles and responsibilities of all health sector actors. There is no blueprint for managing this 
kind of change (Peters et al 2009; Bloom and Wolcott 2013). Although strong leadership by 
the state is important, it is also important that local and international businesses and civil 
society organizations participate in the construction of effective institutions. There is relatively 
little systematic knowledge on strategies for managing change in a pluralistic health system. 
It requires mutual learning by all stakeholders (Bennett et al 2014). The Centre for Business 
and Development will contribute to this learning by supporting the generation and 
dissemination of systematic knowledge of what works and why through the following 
activities: 
 
• Consultative meetings to facilitate sharing of knowledge, including tacit knowledge, 
between stakeholders and to build mutual learning between these stakeholders. 
• Analytic studies of the organisation, functioning and political influences on the 
performance of health markets. 
• Identification and assessment of the impact of emergent innovations on the 
performance of health systems in providing access to safe, effective and affordable 
services 
• Participation in partnerships aimed at introducing innovations in information and 
communications technology and low cost diagnostics and systematic assessment of 
the experience 
• Participation in studies of the creation of regulatory partnerships to address defined 
health sector problems. 
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Annex I 
 
Addressing the challenge of anti-microbial resistance in pluralistic health systems 
 
The problem 
There is a large amount of evidence about the factors that contribute to the emergence of 
bacteria that are resistant to most common anti-microbial drugs. There is a growing global 
consensus that these bacteria represent a major public health challenge and could lead to 
the spread of infections for which there are not effective treatments. There is also a growing 
recognition of the risk of these infections spreading across national boundaries. The WHO 
has declared this to be a major global challenge. There is very little disagreement about the 
need for action. 
 
Key stakeholders 
 
• Producers and distributors of anti-microbial drugs at all levels in the value chain 
• Health service providers and drug retailers who supply the drugs to clients including 
large numbers of informal providers 
• Associations of service providers including professional bodies (doctors, pharmacists 
and so forth) and associations of informal providers. 
• Users of anti-microbial drugs 
• Associations representing service users 
• Social entrepreneurs with a particular interest in health system reform 
• Government regulatory agencies in countries with pluralistic health systems 
• Government regulatory agencies in other countries, who are concerned about cross-
border spread 
• Global organizations such as the World Health Organization 
 
Framing the issues 
The dominant view is the need for regulatory action to reduce excessive use of anti-microbial 
drugs and ensure that people take a full course of treatment. In countries with pluralistic 
health systems, this would mean strict enforcement of laws that require a doctor’s 
prescription to obtain a drug. In many countries professional associations have been 
lobbying for this kind of action for many years. However, for measures that deny people 
access to these drugs through existing channels to gain political legitimacy, alternative 
mechanisms would be needed to provide access to treatment of infections. This could be 
achieved by a well-funded government health service.  
 
An alternative view begins by recognising the functioning of informal markets. They have 
made anti-microbial drugs widely available for many years although there are serious 
problems with the quality of the products, a tendency to over prescribe them and a 
willingness to supply partial doses. There is some evidence that the easy availability of anti-
microbial products had contributed to reductions in mortality amongst the poor. This suggests 
that there is a tension between the need of the poor for easy access to anti-microbials and 
the concern by the global community about the emergence of drug resistance. Is it possible 
to create new kinds of partnership for providing access to drug treatment of common 
infections?  
 
Roles and responsibilities of stakeholders 
The combination of strict enforcement of laws to restrict access to anti-microbial drugs and of 
rapid expansion of publicly organised health services to provide universal access will mainly 
involve government regulatory agencies and major reforms to the management of public 
health services. Where this is unrealistic, an alternative approach will be needed that 
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engages with the existing health markets. This will begin by mapping the key stakeholders 
(figure 1): 
 
• Providers of medical advice and common drugs mostly operate as small businesses. 
They have strong incentives to supply drugs that they believe will work. They 
frequently supply more than one anti-microbial drug plus an analgesic and or a 
steroid to reduce symptoms rapidly. Drug wholesalers often provide additional 
incentives for them to supply particular products. In many cases there is strong 
competition between informal businesses and pharmacies and private medical 
practices run by a licensed professional.  
 
• Drug wholesalers are competing for markets for their products. They provide 
information to the retailers, but have little incentive to inform them about public goods 
issues, side-effects of drugs and so forth. In many pluralistic health systems there are 
a variety of wholesalers who compete on quality and price. If the regulatory system is 
weak, there may be a major problem with the quality of products. 
 
• Drug producers are also competing for markets. Many common anti-microbial drugs 
are no longer covered by patents and are supplied by generic manufacturers. They 
have little incentive to worry about issues of the emergence of resistance 
 
• Large R&D-based pharmaceutical companies have not given high priority to the 
development of new anti-microbial agents, because of a perceived lack of a market. 
They have little incentive to invest in products, and to withhold them from the market 
in anticipation of the emergence of resistance to existing products. 
 
The challenge is to build a partnership for tackling anti-microbial resistance that will enable 
the existing market actors to supply easy access to appropriate drugs, while altering the 
structure of incentives to reduce oversupply of these products and to encourage people to 
take a full course of treatment. This would need to involve some of each of the following: 
 
• Drug wholesalers who have direct contact with drug retailers 
• Drug producers who are seeking stable markets for their products 
• Large pharmaceutical companies, who do not have a major stake in the market for 
common anti-microbials, but who are seeking a long-term presence in these countries 
• National regulatory agencies and the government health service 
• Global governance arrangements, which could set norms and standards concerning 
the functioning of national anti-microbial markets 
 
An initiative to alter the performance of markets for anti-microbials could apply all four 
regulatory strategies: 
 
• Strengthening enforcement of regulation of drug quality and access to second or third 
line anti-microbials 
• Partnerships between informal providers and the formal health and pharmaceutical 
sector to realign incentives regarding the supply of anti-microbials 
• Consumer oriented approaches to increase awareness of when and how to use anti-
microbials and of the threat of emergence of resistant organisms 
• Collaboration-oriented approaches for a focused effort to find ways to provide 
universal access to antimicrobials while reducing the risk of resistance. 
 
Management of conflicts of interest 
The intervention would take place in the context of highly competitive markets for 
pharmaceuticals and for the provision of health services. The purpose of the proposed 
partnership would be to find ways to address a specific problem in this context. There is 
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always a risk that one member could use the partnership to promote its own interests. This 
risk can be reduced by widening the membership of the partnership and by agreeing ways to 
monitor its performance. 
 
Stewardship 
The government has an important role to play in overseeing the creation and management of 
this kind of partnership. However, it could involve other strong actors, who can express the 
interests of the different stakeholders. These could be strong NGOs, a variety of citizen 
organisations, faith based organisations, professional associations and so forth. There may 
be a need to organise activities aimed at strengthening the capacity of all stakeholders to 
participate effectively in this kind of partnership. 
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